Common HIV treatments may aid Alzheimer’s disease patients

Alzheimer's disease (AD) currently afflicts nearly seven million people in the U.S. With this number expected to grow to nearly…

02xl Admin 02xl Admin

Hansa starts dosing in Phase III trial in anti-GBM disease

Sweden-based Hansa Biopharma doses first anti-GMB patient with imlifidase in a Phase III trial. Credit: Shutterstock/Marko Aliaksandr Hansa Biopharma has…

Blended antioxidant supplement improves cognition and memory in aged mice

Cell damage from oxidative stress is a major underlying cause of age-related cognitive and muscle strength decline. Antioxidants can reduce…

02xl Admin 02xl Admin
- Advertisement -
Ad imageAd image